Immorta Bio is excited to share that our President and Chief Scientific Officer, Dr. Thomas Ichim, was featured in BioFuture 2024's "Unlocking Longevity: Innovations, Investments, and the Future of Biotech" panel. The discussion delved into the progression of the science of aging and advancements in the field, with panelists highlighting stem cell research as the cornerstone of emerging longevity therapies. Dr. Ichim also introduced Immorta Bio's mission and goals, sharing insights into our flagship products, SenoVax™ and Stem Cell Revivify™, along with our developmental progress.

BioFuture was held in New York City on October 28-30, 2024. The event is described as "The Nexus for Innovators, Investors, and Changemakers to Rethink and Shape the Future of Healthcare," focusing on topics regarding "biopharma, digital medicine, big data, TechBio, AI, and more."

We would like to extend our gratitude to BioFuture for inviting Immorta Bio to the panel and to our audience for engaging with us, asking questions, and contributing to a meaningful longevity discussion.

Follow Immorta Bio

X

LinkedIn

Bio Future

‍